Tian Zhang, MD

Associate Professor of Medicine

Member of the Duke Cancer Institute

Campus mail DUMC 103861, Durham, NC 27710

Phone (919) 668-4667

Email address tian.zhang2@duke.edu

Education and Training

Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
M.H.S., Duke University School of Medicine, 2019
M.D., Harvard Medical School, 2009

Grants

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCIN
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of PF-06940434 in Patients with Advanced or Metastatic Solid Tumors
NeoImmune NMTNT110
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (Mirati 516-003)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿)
Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer
The impact of genetic diversity among Akkermansia strains on the effectivenes of immune checkpoint inhibitors in cancer immunotherapies
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512)
Phase II study of AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma
Immune correlates of immunotherapy responses in renal cell carcinoma

Publications

George, Daniel J., Susan Halabi, Elisabeth I. Heath, A Oliver Sartor, Guru P. Sonpavde, Devika Das, Rhonda L. Bitting, et al. “A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.” Cancer 127, no. 16 (August 15, 2021): 2954–65. https://doi.org/10.1002/cncr.33589.

PMID

33951180

Full Text

Wheeler, Stephanie B., Lisa P. Spees, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, et al. “Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.” Jco Oncol Pract, June 17, 2021, OP2001082. https://doi.org/10.1200/OP.20.01082.

PMID

34138665

Full Text

Min, Yuanzeng, Kyle C. Roche, Shaomin Tian, Michael J. Eblan, Karen P. McKinnon, Joseph M. Caster, Shengjie Chai, et al. “Author Correction: Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.” Nat Nanotechnol 16, no. 6 (June 2021): 743–44. https://doi.org/10.1038/s41565-021-00864-w.

PMID

33580223

Full Text

Grivas, P., A. R. Khaki, T. M. Wise-Draper, B. French, C. Hennessy, C. -. Y. Hsu, Y. Shyr, et al. “Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.” Ann Oncol 32, no. 6 (June 2021): 787–800. https://doi.org/10.1016/j.annonc.2021.02.024.

PMID

33746047

Full Text

Koontz, Bridget F., Karen E. Hoffman, Susan Halabi, Patrick Healy, Monika Anand, Daniel J. George, Michael R. Harrison, et al. “Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.” Int J Radiat Oncol Biol Phys 109, no. 5 (April 1, 2021): 1271–78. https://doi.org/10.1016/j.ijrobp.2020.11.059.

PMID

33259932

Full Text

Laccetti, Andrew L., Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, et al. “Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.” Cancer Med 10, no. 7 (April 2021): 2341–49. https://doi.org/10.1002/cam4.3812.

PMID

33650321

Full Text

Zhang, Tian, and Daniel J. George. “Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.” Nat Med 27, no. 4 (April 2021): 586–88. https://doi.org/10.1038/s41591-021-01320-x.

PMID

33820997

Full Text

Kao, Chester, Eric Powers, Yuan Wu, Michael B. Datto, Michelle F. Green, John H. Strickler, Neal E. Ready, Tian Zhang, and Jeffrey M. Clarke. “Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.” Clin Lung Cancer, March 27, 2021. https://doi.org/10.1016/j.cllc.2021.03.017.

PMID

33972172

Full Text

Dinan, Michaela A., Mihaela V. Georgieva, Yanhong Li, Tian Zhang, Michael Harrison, Rahul Shenolikar, and Charles D. Scales. “Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.” J Geriatr Oncol 12, no. 2 (March 2021): 298–304. https://doi.org/10.1016/j.jgo.2020.08.005.

PMID

32912737

Full Text

Kao, Chester, Daniel J. George, and Tian Zhang. “An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).” Oncologist 26, no. 3 (March 2021): e508–11. https://doi.org/10.1002/onco.13617.

PMID

33251710

Full Text

Tian Zhang, MD

Education and Training

Grants

Publications

Pages